Treatment of chronic spontaneous urticaria: Immunomodulatory approaches.
(2018) Clinical Immunology — Vol. 190, p. 53-63 (2018)
Files
2018_de_Montjoye_Clin_Immunol.pdf
Open Access - Adobe PDF
- 767.78 KB
Details
- Authors
- Abstract
- This paper summarizes and reviews the mechanisms of action and data concerning efficacy of recommended treatments as well as other treatments that have been tested, independently of the outcomes, in the management of chronic spontaneous urticaria. Due to the central role of mast cells, basophils and histamine in the pathophysiology of this disease, H1-antihistamines remain the first-line treatment. However, current knowledge about this complex disease, also recognizes an important role for T lymphocytes, B lymphocytes, and autoantibodies. Implications of these others mediators thus provide further targets for treatment. Indeed, agents previously used to treat other autoimmune and inflammatory diseases, have demonstrated efficacy in chronic spontaneous urticaria and are therefore potential therapeutic alternatives for antihistamine unresponsive patients.
- Affiliations
Citations
De Montjoye, L., Herman, A., Nicolas, J.-F., & Baeck, M. (2018). Treatment of chronic spontaneous urticaria: Immunomodulatory approaches. Clinical Immunology, 190, 53-63. https://doi.org/10.1016/j.clim.2017.11.004 (Original work published 2018)